Yeramaneni, 7,158 patient famotidine prophylaxis study: 51% lower mortality [p=0.22] https://c19p.org/yeramaneni
copied to clipboard
Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System
et al., Gastroenterology, doi:10.1053/j.gastro.2020.10.011
Retrospective 7,158 hospitalized COVID-19 patients in the USA, showing higher risk or mortality with in-hospital famotidine use and lower risk with pre-existing use, without statistical significance in both cases.
|
risk of death, 51.0% lower, OR 0.49, p = 0.22, treatment 351, control 6,807, adjusted per study, home use, multivariable, RR approximated with OR.
|
|
risk of death, 59.0% higher, OR 1.59, p = 0.09, treatment 410, control 746, adjusted per study, hospital use, multivariable, RR approximated with OR, late treatment result.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Yeramaneni et al., 28 Feb 2021, retrospective, USA, peer-reviewed, 6 authors, study period 11 February, 2020 - 8 May, 2020.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.